STRATEC SE

Notice of Dividend Amount • Mar 24, 2010

News Details

Ad-hoc | 24 March 2010 09:47

STRATEC’s Board of Management proposes 29% increase in dividend to Euro 0.45 per share

STRATEC Biomedical Systems AG / Dividend

24.03.2010 09:47

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC's Board of Management proposes 29% increase in dividend to Euro
0.45 per share

Birkenfeld, March 24, 2010

In view of the current and expected future business performance of the
STRATEC Group, the Board of Management of STRATEC Biomedical Systems AG,
Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard) today resolved to
present to the Supervisory Board a proposal for the appropriation of
profits for the Annual General Meeting which foresees raising the dividend
for the 2009 financial year by 29% to Euro 0.45 per share (previous year:
Euro 0.35).

---

Information and Explaination of the Issuer to this News:

Forthcoming publication dates

The final approved figures for the 2009 financial year will be published on
April 13, 2010 and will be discussed in the annual results teleconference
for analysts, investors and press representatives. The 2009 Annual Report
will also be available for downloading from the company's internet site on
April 13, 2010.

The Annual General Meeting of STRATEC Biomedical Systems AG will be held in
Pforzheim on Friday, May 21, 2010. The invitation to the Annual General
Meeting will be forwarded to STRATEC shareholders via their depositing
banks in good time ahead of the Annual General Meeting.

The interim report as of March 31, 2010 will be published on April 28,
2010.

About STRATEC

STRATEC Biomedical Systems AG (www.stratec-biomedical.de) designs and
manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-mail: ir@stratec-biomedical.de

24.03.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---